Findings set the stage for further investigation of hSFRP2 mAb as a targeted therapy for triple-negative breast cancer.
Mice lacking the extracellular matrix protein tenascin-C showed a reduced ability to repair muscular damage compared to controls.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback